Gilead’s Q1 shows HIV momentum remains powerful, but diversification is still unfinished
Gilead’s HIV engine is roaring again. But acquisition costs and oncology pressure leave investors asking how durable the reset really is.
Why Q Care Plus is blending PrEP, birth control, and sexual health in one telehealth platform
Q Care Plus adds ED, hair loss, and birth control services to its virtual platform. Find out how this reshapes stigma-free access to sexual wellness care.